Director at Precigen (PGEN) converts 71,839 vested RSUs into shares

Rhea-AI Filing Summary

PRECIGEN, INC. director Cesar L. Alvarez exercised restricted stock units that had fully vested into common shares. On March 13, 2026, 71,839 RSUs vested in full and were converted into the same number of common shares at no cash exercise price. Following this compensation-related exercise-and-hold transaction, he directly owned 782,909 shares of Precigen common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALVAREZ CESAR L

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		M		71,839	A	(1)	782,909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		M			71,839	(2)	(2)	Common Stock	71,839	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vested in full on March 13, 2026.

	/s/ Cesar L. Alvarez, by Donald P. Lehr, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Precigen (PGEN) director Cesar L. Alvarez report?

Director Cesar L. Alvarez reported exercising restricted stock units into common shares. He converted 71,839 RSUs into the same number of Precigen common shares as part of a compensation-related vesting event, with no open-market purchase or sale indicated.

How many Precigen (PGEN) shares did Cesar L. Alvarez acquire in this Form 4?

Cesar L. Alvarez acquired 71,839 Precigen common shares through the exercise of restricted stock units. Each RSU represented a right to receive one share, so 71,839 vested RSUs became 71,839 common shares in this transaction.

What is Cesar L. Alvarez’s Precigen (PGEN) share ownership after the reported transaction?

After the reported transaction, Cesar L. Alvarez directly owned 782,909 shares of Precigen common stock. This figure reflects his position following the conversion of 71,839 restricted stock units into common shares on March 13, 2026.

Were the Precigen (PGEN) restricted stock units granted to Cesar L. Alvarez fully vested?

Yes. The filing notes that the restricted stock units vested in full on March 13, 2026. Once vested, 71,839 RSUs were converted into an equal number of Precigen common shares, completing this compensation-related equity award event.

Did Cesar L. Alvarez buy or sell Precigen (PGEN) shares on the open market?

The Form 4 shows a derivative exercise, not an open-market trade. Alvarez converted 71,839 vested restricted stock units into common shares at a stated price of $0.00 per share, with no reported open-market buying or selling activity.

What type of security did the Precigen (PGEN) director convert into common stock?

He converted restricted stock units into common stock. Each RSU represented a contingent right to receive one Precigen common share, and 71,839 RSUs vested and were exchanged for 71,839 common shares in this transaction.